Semi-Annual Report — FY2026 H1
What Cyfuse Biomedical K.K. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-14View the original on EDINET
How much it says
53Typical
What moved here
28named for the first time
Its own wording
43terms
Which filing this is
11/ 11newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the current interim accounting period, business activities and product development progressed in the regenerative medicine, drug-discovery support and device fields. In the device field, the company reported the development and launch of sales of the new CAP device. Revenue increased year on year, but the company recorded an interim net loss. Financially, total assets declined, partly because cash and deposits decreased.
Komori's summary of this document, not the document's own words.53Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
61
Detailed
60
Detailed
50
Typical
0
Almost nothing
68
Detailed
55
Typical
31
Thin
53
Typical
79
Very detailed
50
Typical
R&D spend2億円Money spent making new things.
Cash left over-6億円Cash from the business, less what went into equipment.
Spent on equipmentNot disclosedThis document does not carry the figure.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.